Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6481 AL 6495

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease

Rockwood K, Fay S, Gorman M.

Int J Geriatr Psychiatry. 2010 Feb;25(2):191-201. doi: 10.1002/gps.2319.

Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2

Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, Spanò A, Gallo D, Mungari P, Consoli D, Bosco D.

J Neurol Sci. 2010 Jan 15;288(1-2):112-6. doi: 10.1016/j.jns.2009.09.022.

Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment

Modrego PJ.

J Alzheimers Dis. 2010;21(4):1077-87. doi: 10.3233/jad-2010-100153.

Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease

Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M, Williams P.

Curr Alzheimer Res. 2010 Aug;7(5):374-85. doi: 10.2174/156720510791383831.

An update on clinical proteomics in Alzheimer's research

Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T.

J Neurochem. 2010 Mar;112(6):1386-414. doi: 10.1111/j.1471-4159.2009.06558.x. Epub 2009 Dec 24.

Management of behavioral problems in Alzheimer's disease

Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C.

Int Psychogeriatr. 2010 May;22(3):346-72. doi: 10.1017/S1041610209991505. Epub 2010 Jan 25.

Dissecting dementia, depression, and drug effects in older adults

Sherrod RA, Collins A, Wynn S, Gragg M.

J Psychosoc Nurs Ment Health Serv. 2010 Jan;48(1):39-47. doi: 10.3928/02793695-20091204-01.

Galantamine for Alzheimer's disease

Prvulovic D, Hampel H, Pantel J.

Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):345-54. doi: 10.1517/17425251003592137.

A view from the USA on the Alzheimer's disease international position paper

Rubenstein LZ.

J Nutr Health Aging. 2010 Feb;14(2):104. doi: 10.1007/s12603-010-0019-8.

The primary care physician and Alzheimer's disease: an international position paper

Villars H, Oustric S, Andrieu S, Baeyens JP, Bernabei R, Brodaty H, Brummel-Smith K, Celafu C, Chappell N, Fitten J, Frisoni G, Froelich L, Guerin O, Gold G, Holmerova I, Iliffe S, Lukas A, Melis R, Morley JE, Nies H, Nourhashemi F, Petermans J, Ribera Casado J, Rubenstein L, Salva A, Sieber C, Sinclair A, Schindler R, Stephan E, Wong RY, Vellas B.

J Nutr Health Aging. 2010 Feb;14(2):110-20. doi: 10.1007/s12603-010-0022-0.

Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper

Nourhashémi F, Olde Rikkert MG, Burns A, Winblad B, Frisoni GB, Fitten J, Vellas B.

J Nutr Health Aging. 2010 Feb;14(2):121-30. doi: 10.1007/s12603-010-0023-z.

Neurochemical basis for symptomatic treatment of Alzheimer's disease

Francis PT, Ramírez MJ, Lai MK.

Neuropharmacology. 2010 Sep-Oct;59(4-5):221-9. doi: 10.1016/j.neuropharm.2010.02.010. Epub 2010 Feb 13.

[Institutionalization of mentally ill in old age]

Riedel-Heller SG, Luppa M, König HH.

Psychiatr Prax. 2010 Mar;37(2):53-5. doi: 10.1055/s-0029-1223514. Epub 2010 Feb 24.

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease

Cumbo E, Ligori LD.

Epilepsy Behav. 2010 Apr;17(4):461-6. doi: 10.1016/j.yebeh.2010.01.015. Epub 2010 Feb 25.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias